SDLBevacizumab Biosimilar (Mvasi) Concentrate For Infusion 100 mg, 400 mg
MSHLBevacizumab (Avastin) Concentrate For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
For cancer treatment in line with HSA-registered indication(s).
MSHLBevacizumab biosimilar (Mvasi) Concentrate For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
For cancer treatment.
MSHLBevacizumab (Avastin) Concentrate For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
1) Atezolizumab in combination with bevacizumab (non-subsidised brand), and platinum-doublet chemot...
MSHLBevacizumab (Avastin) Concentrate For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
1) Atezolizumab in combination with bevacizumab (non-subsidised brand), and platinum-doublet chemotherapy, for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who had not received prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC.
2) Atezolizumab in combination with bevacizumab (non-subsidised brand) for treating advanced unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.
MSHLBevacizumab (Avastin) Concentrate For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
Olaparib in combination with bevacizumab (non-subsidised brand) as maintenance treatment of patient...
MSHLBevacizumab (Avastin) Concentrate For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
Olaparib in combination with bevacizumab (non-subsidised brand) as maintenance treatment of patients with advanced homologous recombination deficiency (HRD) positive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab.
Treatment with olaparib should be continued until disease progression or unacceptable toxicity or for a maximum of 24 months.
MSHLBevacizumab biosimilar (Mvasi) Concentrate For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
1) Atezolizumab in combination with bevacizumab biosimilar (subsidised brand), and platinum-doublet...
MSHLBevacizumab biosimilar (Mvasi) Concentrate For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
1) Atezolizumab in combination with bevacizumab biosimilar (subsidised brand), and platinum-doublet chemotherapy, for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who had not received prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC.
2) Atezolizumab in combination with bevacizumab biosimilar (subsidised brand) for treating advanced unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.
MSHLBevacizumab biosimilar (Mvasi) Concentrate For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
Olaparib in combination with bevacizumab biosimilar (subsidised brand) as maintenance treatment of ...
MSHLBevacizumab biosimilar (Mvasi) Concentrate For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
Olaparib in combination with bevacizumab biosimilar (subsidised brand) as maintenance treatment of patients with advanced homologous recombination deficiency (HRD) positive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab biosimilar.
Treatment with olaparib should be continued until disease progression or unacceptable toxicity or for a maximum of 24 months.
MSHLBevacizumab biosimilar (Vegzelma) Concentrate For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
For cancer treatment.
MSHLBevacizumab (Vegzelma) Concentration For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
Olaparib in combination with bevacizumab (non-subsidised brand) as maintenance treatment of patient...
MSHLBevacizumab (Vegzelma) Concentration For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
Olaparib in combination with bevacizumab (non-subsidised brand) as maintenance treatment of patients with advanced homologous recombination deficiency (HRD) positive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab.
Treatment with olaparib should be continued until disease progression or unacceptable toxicity or for a maximum of 24 months.
MSHLBevacizumab (Vegzelma) Concentration For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
1) Atezolizumab in combination with bevacizumab (non-subsidised brand) for treating advanced unrese...
MSHLBevacizumab (Vegzelma) Concentration For Solution For Infusion 100 mg/4 mL, 400 mg/16 mL
1) Atezolizumab in combination with bevacizumab (non-subsidised brand) for treating advanced unresectable hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system.
2) Atezolizumab in combination with bevacizumab (non-subsidised brand), and platinum-doublet chemotherapy, for the treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who had not received prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for metastatic NSCLC.